Mather Group LLC. Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Mather Group LLC. bought a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 548 shares of the biotechnology company’s stock, valued at approximately $171,000.

A number of other institutional investors have also added to or reduced their stakes in AXON. QRG Capital Management Inc. acquired a new position in Axon Enterprise during the third quarter worth $531,000. Envestnet Portfolio Solutions Inc. acquired a new position in Axon Enterprise during the third quarter worth $787,000. Envestnet Asset Management Inc. increased its holdings in Axon Enterprise by 22.5% during the third quarter. Envestnet Asset Management Inc. now owns 74,479 shares of the biotechnology company’s stock worth $14,821,000 after buying an additional 13,704 shares during the last quarter. FMR LLC increased its holdings in Axon Enterprise by 12.9% during the third quarter. FMR LLC now owns 558,139 shares of the biotechnology company’s stock worth $111,064,000 after buying an additional 63,611 shares during the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Axon Enterprise by 6.6% in the third quarter. LPL Financial LLC now owns 43,559 shares of the biotechnology company’s stock valued at $8,668,000 after purchasing an additional 2,715 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on AXON shares. JMP Securities reiterated a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Morgan Stanley upped their price objective on shares of Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, April 26th. Barclays upped their price objective on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday, May 8th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Finally, StockNews.com downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Axon Enterprise Trading Down 0.1 %

Shares of Axon Enterprise stock opened at $293.14 on Friday. The firm has a 50-day moving average of $296.12 and a 200-day moving average of $282.26. The stock has a market cap of $22.12 billion, a PE ratio of 85.71 and a beta of 0.91. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same quarter in the previous year, the business posted $0.51 earnings per share. Axon Enterprise’s quarterly revenue was up 34.3% on a year-over-year basis. As a group, sell-side analysts forecast that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insider Buying and Selling

In related news, President Joshua Isner sold 44,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the completion of the sale, the president now owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, President Joshua Isner sold 44,000 shares of the stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.96, for a total value of $13,638,240.00. Following the completion of the transaction, the president now owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 308 shares of the stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the completion of the transaction, the director now directly owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The disclosure for this sale can be found here. Insiders sold 89,447 shares of company stock valued at $27,684,677 over the last quarter. 6.10% of the stock is owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.